Showing results (41-50 of 73) with videos related to
Sort By:
Pageof 8
Clinical Genitourinary Cancer|February 10, 2015
GermLine Variation in Superoxide Dismutase-2 (SOD2) and Survival Outcomes After Radiation Therapy for Prostate Cancer: Results of a Test and Validation Set AnalysisDanielle N Margalit, Kristina M Jordahl, Lillian Werner, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 16, 2011
Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemiaPhilip C Amrein, Eyal C Attar, Tak Takvorian, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2016
A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local TherapyRana R McKay, Amado J Zurita, Lillian Werner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2019
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced MelanomaMeredith M Regan, Lillian Werner, Sumati Rao, et al.Cytotherapy|September 6, 2018
Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapyJoana M Murad, Susanne H Baumeister, Lillian Werner, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 30, 2016
A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate CancerRana R McKay, Lillian Werner, Elahe A Mostaghel, et al.Clinical Genitourinary Cancer|January 19, 2016
Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer CenterVinayak Muralidhar, Meredith M Regan, Lillian Werner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancerMing Yang, Wanling Xie, Elahe Mostaghel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2012
Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemiaJennifer R Brown, Megan Hanna, Bethany Tesar, et al.Plos One|August 2, 2014
Identification of ALK gene alterations in urothelial carcinomaJoaquim Bellmunt, Shamini Selvarajah, Scott Rodig, et al.Pageof 8